Professor Caldas has held the Chair of Cancer Medicine at the University of Cambridge since 2002. He heads the Breast Cancer Functional Genomics Laboratory at the Cancer Research UK Cambridge Research Institute. He is an Honorary Consultant Medical Oncologist at Addenbrooke’s Hospital, Head of the Cambridge Experimental Cancer Medicine Centre and Director of the Cambridge Breast Cancer Research Unit which opened at Addenbrooke’s Hospital in 2008. He is a Fellow of the American
College of Physicians, the Royal College of Physicians, and the Royal College of Pathologists.  He was elected a Fellow of the Academy of Medical Sciences in 2004, and of the European Academy of Cancer Sciences in 2010.
Professor Carlos Caldas is a graduate from the University of Lisbon Medical School and trained in Internal Medicine at UT Southwestern, Dallas and Medical Oncology at Johns Hopkins Hospital, Baltimore. He then completed a research fellowship at the Institute of Cancer Research in London. In 1996 he moved to Cambridge where he has directed a research group working on the genetic alterations underlying human epithelial malignancies, with a particular focus on breast cancer. His current research focus is in the functional genomics of breast cancer and its biological and clinical implications. He has also a research program on the genetics of gastric cancer. His main clinical interest is in breast cancer chemotherapy and novel molecularly targeted therapies.

Nancy Cox is Director of the Vanderbilt Genetics Institute at the Vanderbilt School of Medicine, Nashville, TN, Director of the Division of Genetic Medicine, and Mary Phillips Edmonds Gray Professor of Genetics at Vanderbilt. She is a quantitative human geneticist with a long-standing research program in identifying and characterizing the genetic component to common human diseases. Her Lab develops methods for analyzing genetic and genomic data and applies these to the analysis of genome data on common diseases. She is researching large-scale integration of genomic with other ‘-omics’ data, as well as with biobank and electronic medical records data.
Dr. Cox’s laboratory develops methods for analyzing genetic and genomic data and then applies those methods to the analysis of genome data on common diseases and translational phenotypes, such as pharmacogenomics traits, with a particular focus now on the integration of information on genome function with methods for the analysis of genome data on breast cancer, diabetes and its complications, autism, schizophrenia and bipolar disorder, Tourette Syndrome and OCD. Her work has also been funded to develop methods for the analysis of 1,000 Genomes Project data as well as GTEx Project data. In addition, through her activities as VGI Director, she will be enhancing the number of samples with genome interrogation in BioVU and plans to make the results of new types of statistical genomics analyses on BioVU data available to the Vanderbilt community of scientists.

Mary-Claire King, PhD, is American Cancer Society Professor at the University of Washington, Seattle. She was the first to show that breast cancer is inherited in some families, as the result of mutations in the gene that she named BRCA1. In addition to inherited breast and ovarian cancer, her research interests include the genetic bases of schizophrenia, genetic disorders in children, and human evolution. She pioneered the use of DNA sequencing for human rights investigations.
Prof. King has been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the Institute of Medicine, the American Philosophical Society, and as a foreign member of the French Academy of Sciences. She has served on the Advisory Committee to the Director of NIH, the National Commission on Breast Cancer of the President’s Cancer Panel, multiple councils and study sections of the NIH, and as past president of the American Society of Human Genetics. In 2014, she received the Lasker Special Achievement Award for Medical Research and in 2016 the United States National Medal of Science.

Jayaraj Rajagopal is a Professor of Medicine, Harvard Medical School, and Principal Investigator both at the Centre for Regenerative Medicine, Massachusetts General Hospital, and the Harvard Stem Cell Institute. His specialties are stem cell and regenerative biology. His lab focuses on lung regeneration and the application of developmental biology to human disease, using innovative cell culturing techniques to study respiratory disorders.
He is also an Investigator at the New York Stem Cell Foundation. Jay has MD and PhD degrees from Harvard University. He was awarded the Dr Susan Lim Award for Outstanding Young Investigator at the 2017 International Society for Stem Cell Research (ISSCR) meeting in Boston (MA, USA). Prof. Rajagopal inquiries into the mechanisms underlying embryonic lung development and adult lung epithelial regeneration serve as a framework within which he seeks to understand how the reactivation and distortion of normal developmental processes results in human lung disease. In a parallel effort, he studies the murine trachea as a robust model of organ regeneration and seeks to answer longstanding historical questions in regeneration biology using this highly reproducible, rapid experimental model.

Vardit Ravitsky is Full Professor at the Bioethics Program, School of Public Health, University of Montreal and Senior Lecturer on Global Health and Social Medicine at Harvard Medical School. Her research focuses on the ethics of genomics and reproduction and is funded by Canada’s leading funding agencies. She published over 170 articles and commentaries on bioethical issues. Ravitsky is President of the International Association of Bioethics and Director of Ethics and Health at the Center for Research on Ethics. She is a 2020 Trudeau Foundation Fellow and Chair of the Foundation’s COVID-19 Impact Committee, as well as Fellow of the Canadian Academy of Health Sciences and of the Hastings Center. She is member of the Standing Committee on Ethics of the Canadian Institutes of Health Research (CIHR) and of the Institute Advisory Board of CIHR’s Institute of Genetics. She is also member of the National Human Genome Research Institute’s (NHGRI) Genomics & Society Working Group. Ravitsky's research covers a variety of topics such as pre-implantation genetic testing; gamete donation; epigenetics; prenatal testing; germline and somatic gene editing; and mitochondrial replacement. She holds a PhD from Bar-Ilan University in Israel. Previously, she was faculty at the Department of Medical Ethics, School of Medicine, at the University of Pennsylvania. She was also a Senior Policy Advisor at CIHR's Ethics Office and a GE3LS consultant to Genome Canada (GE3LS = genomics and its ethical, economic, environmental, legal and social implications).

Prof. Aviv Regev, a computational and systems biologist, is a professor of biology at MIT, a Howard Hughes Medical Institute Investigator, the Chair of the Faculty and the director of the Klarman Cell Observatory and Cell Circuits Program at the Broad Institute of MIT and Harvard, and co-chair of the organizing committee for the international Human Cell Atlas project.
She studies the molecular circuitry that governs the function of mammalian cells in health and disease and has pioneered many leading experimental and computational methods for the reconstruction of circuits, including in single-cell genomics.
Regev is a recipient of the NIH Director’s Pioneer Award, a Sloan fellowship from the Sloan Foundation, the Overton Prize from the International Society for Computational Biology (ISCB), the Earl and Thressa Stadtman Scholar Award from the American Society of Biochemistry and Molecular Biology, and the ISCB Innovator Award, and she is a ISCB Fellow (2016). She is the inaugural recipient of the FASEB Excellence in Science Mid-Career Investigator Award and is an elected member of the National Academy of Sciences.
Regev received her M.Sc. from Tel Aviv University, studying biology, computer science, and mathematics in the Interdisciplinary Program for the Fostering of Excellence. She received her Ph.D. in computational biology from Tel Aviv University.

Prof. Fiona Watt is Executive Chair of the Medical Research Council (MRC) and is recognized internationally for her work on stem cells in healthy and diseased skin. Fiona obtained her first degree from Cambridge University and a DPhil in cell biology from the University of Oxford. Following postdoctoral training at Massachusetts Institute of Technology, she established her first research group at the Kennedy Institute for Rheumatology and then spent 20 years at the Cancer Research UK London Research Institute (now part of the Francis Crick Institute).
She helped to establish the Cancer Research UK Cambridge Research Institute and the Wellcome Trust Centre for Stem Cell Research, and in 2012 she moved to King's College London to found the Centre for Stem Cells and Regenerative Medicine.
Fiona is a Fellow of the Royal Society, a Fellow of the Academy of Medical Sciences and an Honorary Foreign Member of the American Academy of Arts and Sciences. Her awards include the American Society for Cell Biology (ASCB) Women in Cell Biology Senior Award, Presidency of the International Society for Stem Cell Research, the Hunterian Society Medal and the FEBS/EMBO Women in Science Award. In 2016 she was awarded Doctor Honoris Causa of the Universidad Autonoma de Madrid.